Leukemia

Researchers at UAB found that patients aged younger than 65 who were unmarried, lived in lower-income areas, and who were uninsured or Medicaid beneficiaries were at significantly higher risk of premature mortality.

Watching, waiting and then choosing from a bevy of new treatments can be a good strategy for many with CLL.

The investigational agent venetoclax has successfully met the primary endpoint of a phase 2 study as a treatment for patients with high-risk relapsed or refractory chronic lymphocytic leukemia.

For some, working after cancer means switching careers to pursue a passion.

Adding the targeted drug Imbruvica to a standard combination treatment reduced the risk of disease progression by 80 percent compared with the standard combination alone in patients with pretreated CLL or SLL.

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

The efficacy of Imbruvica (ibrutinib) and Zydelig (idelalisib) in chronic lymphocytic leukemia (CLL) suggests the drugs could potentially replace chemoimmunotherapy completely for some patients.

Stuart Goldberg, hematologist/oncologist at John Theurer Cancer Center, discusses some of the common questions he gets from his patients with chronic myeloid leukemia.

The Food and Drug Administration granted a Fast Track Designation to CPX-351 for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

The vastly improved outlook for patients with chronic lymphocytic leukemia (CLL) was named the American Society of Clinical Oncology's inaugural "Cancer Advance of the Year."

The FDA has updated the label for Gazyva (obinutuzumab) plus chlorambucil to include data from stage 2 of the phase 3 CLL11 study, which detailed an improvement in progression-free survival as a frontline treatment for patients with chronic lymphocytic leukemia.

In a first-in-human study, the drug AG-221 generated long-lasting remissions in patients with acute myeloid leukemia (AML).

Zydelig was approved for several recurrent B-cell cancers, and now new data shows the drug also creates a response in older patients newly diagnosed with CLL or SLL.

The CAR T-cell therapy CTL019 demonstrated an impressive complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

The FDA approved the anti-CD19 immunotherapy Blincyto (blinatumomab) as a treatment for Philadelphia chromosome-negative acute lymphoblastic leukemia.

The CAR T-cell therapy JCAR015 received breakthrough therapy designation as a treatment for patients with relapsed or refractory B-cell ALL.

Approved and investigational agents have improved outcomes for patients with follicular lymphoma; however a growing understanding of the origins and progression of the disease might offer further insights for future clinical development.

Project: EveryChild is collecting biologic samples, such as blood, tissue and other specimens, from children undergoing treatment.